Lifeboat Foundation

Madrid, Spain (Scicasts) — A novel way to count white blood cells without a blood test, simply by applying a small device on the fingertip, is being developed by a team of young bioengineers.

The technology, that combines an optical sensor with algorithms, has already three prototypes on the go and is specially designed to be used on chemotherapy patients, who could know their immune system levels in real time. It could also serve to detect serious infections.

A group of young bioengineers from various countries, including Spaniard Carlos Castro, is developing a portable device capable of counting white blood cells in real time, without requiring a blood test. The system includes an innovative optics sensor through the skin that can observe white cells as they flow past a miniature lens. This new device could be applied to improve the treatment of patients who are left immunosuppressed after chemotherapy treatments and to prevent sepsis.

Read more

BioViva made headlines last week after announcing that they had become the first company to administer anti-aging gene therapy on a human subject. But missing from the press release was exactly how this would work, the likelihood of its success, and the consequences. How better to address this then, than to hear from ‘Patient 0’ herself, Liz Parrish, the company’s CEO who will be undertaking the treatment.

Yesterday (October 11), she took part in a Reddit AMA (Ask Me Anything), answering a range of questions submitted by Reddit users seeking to find out more about this supposedly pioneering study.

Here are ten things we learned from Liz Parrish’s Reddit AMA.

Read more

Organovo is one of the most fascinating companies that we follow–and quite continually–as the dynamic company has kept the momentum rolling with one scientific breakthrough after another.

Famous for the design and creation of functional human tissues for medical applications, we’ve recently also been following Organovo and other partnerships in researching human tissue as well as offering the first 3D bioprinted liver product.

It’s just been recently announced that Uniquest signed a worldwide licensing agreement with Organovo to patent kidney cells from induced pluripotent stem cells (iPSCs). Professor Melissa Little and her team at Uniquest have actually been able to grow kidney tissue which should prove to be helpful in not only drug screening but also disease modeling and cell therapy.

Read more

Elephants are long-lived, and rather large. Given their size and longevity, scientists have pondered what protects them from cancer for a long time. Thanks to new research, we now know.

A mystery unlocked

Cancer is a big problem. A staggering 1 in 2 people born after 1960 in the UK are predicted to develop cancer at some point in their lifetime. We may be living longer, but the extra years are coming with a raised cancer risk. We may be getting better at treatment, but we’re still finding out exactly what causes it, and how we can prevent it from being a danger altogether.

Read more

Aging is 100% genetic, the reason you go from infant to child to adult to old age.

We need to be scrutinizing Progeria, and the case of the girl who died at 20 and was stuck at the age of a toddler, for the key to the genes that will pause aging. While nanotechnology advances parallel with the cure for all diseases.

Once a bucket of genes linked to aging is removed, the lifespan of cells increases significantly, American scientists discovered during ten years of meticulous research, stressing that the results could be applied to humans.

Continue reading “Key to longevity? Blocking over 200 genes boosts lifespan” »

This Week in Science: The First Privately Backed Moon Mission, Using Gene Therapy to Reverse Aging, Artificial Veins and Arteries, and More.

Go here for a clickable image: http://futurism.com/images/this-week-in-science-october-4th-11th-2015/?src=home

Sources
Detecting All Viruses:http://futurism.com/5srzA
Water on Pluto: http://futurism.com/aO2av
Kidney Tissue from Stem Cells: http://futurism.com/DLDON
Converting Algae Blooms into Electrodes: http://futurism.com/w9ez
Fixing Holes in Heart: http://futurism.com/a13Jd
Reversing Aging: http://futurism.com/TjaTL
Private Moon Mission: http://futurism.com/9V626
Artificial Veins: http://futurism.com/rKNzH

Read more

Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as “the woman who wants to genetically engineer you,” she is a humanitarian, entrepreneur and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA) whose mission is to further scientific understanding of biological complexity and the nature and origins of human disease. She is the founder of BioTrove Investments LLC and the BioTrove Podcasts which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine. She is also the Secretary of the American Longevity Alliance (ALA) a 501©(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine with the aim to get governments to consider aging a disease. I am not a medical doctor or scientist. I can not answer details of therapy. I would like to discuss my experience of creating BioViva, organizing the gene therapies, and then finally being able to administer it to the first human.

Read more

Mark Pollock became blind asa young man, and was paralyzed by an accident later. Now, he is taking steps with the help of a robotic exoskeleton.

Read more

BOSTON, Sept. 29, 2015 /PRNewswire/ — Veritas Genetics today announced that the company is making it possible for participants in the Personal Genome Project (PGP) to be among the first to get their whole genome sequenced and interpreted for less than a $1,000.

Led by Veritas Genetics Co-Founder Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Personal Genome Project, PGP is a long-term effort to sequence thousands of complete genomes to enable research into personal genomics and personalized medicine. PGP has more than 16,000 participants worldwide.

The “$1,000 Genome” has long been considered the tipping point when sequencing and interpreting the human genome becomes commonplace and begins to rapidly increase what is known and to dramatically impact healthcare. The catchphrase underscores how far science has come since the actual cost of the Human Genome Project, estimated at $2.7 billion spent over a decade.

Read more